Ricardo J. Alvarez. Dr. Alvarez joined the Board of AquaBounty in March 2021. He is currently the CEO of Hans Kissle Foods, a leading manufacturer of fresh prepared foods. Prior to joining Hans Kissle, he served as CEO of J&K Ingredients, a leading manufacturer of bakery ingredients globally. Prior to J&K Ingredients, he servedglobally, and as President and CEO of various food manufacturing companies including Passport Foods (SVC), LLC, Richelieu Foods, Ruiz Foods, Anita'sAnita’s Foods, Overhill Farms and Raymundo'sRaymundo’s Food Products. In his 2530 years as a leader in the packaged food industry, Dr. Alvarez has implemented growth strategies including new go-to-market initiatives, geographic expansion and innovations of both product and packaging. Dr. Alvarez also has extensive board experience, having served on the boards of Bush Brothers Inc., Clement Pappas Inc., Ruiz Foods and Clear Springs Foods. He currently serves on the board of Phelps Pet Products Inc. Dr. Alvarez brings operational and food industry experience to our Board.



Erin Sharp.  Ms. Sharp joined the Board of AquaBounty in May 2022 and recently retiredafter retiring as Group Vice President of Manufacturing and Enterprise Sourcing for The Kroger Co. (NYSE: KR), where she was a Senior Officer having responsibility for companywide manufacturing, food safety and sourcing.  Prior to her 10 years with The Kroger Co,Co., Ms. Sharp had increasing leadership roles in operations and finance with several large consumer product companies; including Sara Lee, Nestle Dreyer’s and Frito Lay.  She served as a board member for the national nonprofit organization Feeding America as well as several industry boards including American Bakers Association, where she was the first female Chair, MilkPEP and the International Dairy Association.  Ms. Sharp earned a bachelor’s degree from the University of Western Ontario and a Master’s inMaster of Business Administration from the University of Texas. Ms. Sharp brings operational and food industry experience to our Board.    



Gail Sharps Myers. Ms. Sharps Myers joined the Board of AquaBounty in May 2021. She has beenis the Executive Vice President, Chief Legal and Administrative Officer and Chief People OfficerCorporate Secretary at Denny’s Corporation (NASDAQ:DENN), since February 2021. She previously served as Senior Vice President, General Counsel2024, and Secretary of Denny’sshe has held senior executive roles at the company since September 2020 and as Senior Vice President and General Counsel from June 2020 to September 2020. Prior to joining Denny’s, she served as Executive Vice President, General Counsel, Chief Compliance Officer and Secretary of American Tire Distributors, Inc. from May 2018 to May 2020, as Senior Vice President, General Counsel and Secretary at Snyder’s-Lance, Inc. (NASDAQ:LNCE) from January 2015 to March 2018 and as Senior Vice President, Deputy General Counsel, Chief Compliance Counsel and Assistant Secretary from 2014 to 2015 at US Foods, Inc. She received her Doctor of Jurisprudence from The Washington College of Law at The American University, her Master’s inMaster of Business Administration from Arizona State University'sUniversity’s W. P. Carey School of Business and her Bachelor of Arts in Political Science at Howard University. Ms. Sharps Myers’ experience and background make her well suited to serve on our Board.



Christine St.Clare.  Ms. St.Clare joined the Board of AquaBounty in May 2014. She is a former Audit Partner at KPMG LLP (“KPMG”) serving publicly traded companies until 2005, after which she transferred to the Advisory Practice, working in the Internal Audit, Risk and Compliance Practice until her retirement in 2010. She also served a four-year term on KPMG’s Board of Directors,

where she chaired KPMG’s Audit and Finance Committee for three of the four years. She has served on the Board of Directors for Tilray, Inc. (“Tilray”) (NASDAQ:TLRY), from their 2018 IPO through April 2021.  At Tilray, she chaired the Audit Committee and was a member of the Nominating & Governance Committee and the Compensation Committee. She formerly served on the boards of both Fibrocell Science, Inc. (“Fibrocell”), a company that specialized in the development of personalized biologics and Polymer Group, Inc. (“Polymer”), a global manufacturer of engineered materials. Fibrocell was a NASDAQ listed company and Polymer was a Blackstone portfolio company with publicly traded debt.  For both Fibrocell and Polymer, Ms. St.Clare served as the Audit Committee Chair until their respective sales to strategic buyers.  Ms. St.Clare holds a Bachelor of Science in accountingAccounting from California State University at Long Beach and has been a licensed Certified Public Accountant in California, Texas and Georgia. Ms. St.Clare’s background in accounting and support of publicly held companies, as well as her experience with biotechnology, makes her well suited for service on our Board.



Rick Sterling.  Mr. Sterling has served on the Board of AquaBounty since September 2013. He served as the Chief Financial Officer at Precigen Inc. (NASDAQ:PGEN) (“Precigen”) from 2007 through March 2021, including leading them through their initial public offering in 2013. During his term at Precigen, Mr. Sterling was responsible for multiple private and public equity and debt capital raises, financial diligence for and integration of over a dozen acquisitions, SEC reporting and compliance, divestitures of businesses, budgeting, and negotiations of facility leases as well as oversight of human resource and information technology functions. Prior to joining Precigen, he was with KPMG where he worked in the audit practice for over 17 years, with a client base primarily in the healthcare, technology and manufacturing industries. He has a Bachelor of Science in Accounting from Virginia Tech and is a licensed Certified Public Accountant. Mr. Sterling’s background in audit and finance, as well as his experience with technology companies, make him well suited for service on our Board.



Michael Stern. Dr. Stern joined the Board of AquaBounty in May 2022 and is the former CEO of The Climate Corporation and Digital Farming for Bayer Crop Science (“Bayer”) and a member of the Crop Sciences Executive Team.  Before joining Bayer, Dr. Stern had a 30-year career at Monsanto Company (NYSE:MON) (“Monsanto”), where he was a member of Monsanto’s Executive Team and led their Row Crop Business in the Americas.  In addition, Dr. Stern served in a variety of leadership roles at Monsanto, including Vice President of U.S. Seeds and Traits, President of American Seeds, CEO of Renessen LLC, a biotechnology joint venture with Cargill, and Director of Technology for Agricultural Productivity.  Dr. Stern is a member of the Board of Directors of Lavoro Limited (“LVRO”).Limited.  Dr. Stern also serves as Chairman of the Board of Trustees for the Missouri Botanical Garden and served on the board of the Monsanto Fund and the board of Clara Foods, a San Francisco based company focused on developing novel animal proteins from cell culture. Dr. Stern received a Ph.D. in Chemistry from Princeton University, a MSMaster of Science in Chemistry from the University of Michigan and a BSBachelor of Science degree from Denison University.  Dr. Stern’s brings broad experience in the food industry and biotechnology to our Board.



Sylvia Wulf.  Ms. Wulf was appointed Executive Director, President, and Chief Executive Officer of AquaBounty in January 2019. In 2023, Ms. Wulf was elected Chair of the Board of AquaBounty, and she relinquished her position as President, as part of the Company’s leadership progression process. Prior to joining AquaBounty, Ms. Wulf served as a Senior Vice President of US Foods, Inc. (NYSE:USFD), where she had been President of the Manufacturing Division since June 2011. Prior to US Foods, Ms. Wulf held senior positions in Tyson Foods, Inc. (NYSE:TSN), Sara Lee Corporation, and Bunge Corp (NYSE:BG). She is also currently on the Board of Directors and the Executive Committee of both the National Fisheries Institute and the Biotechnology Industry Organization. Ms. Wulf received a Bachelor of Science in Finance from Western Illinois University and a Master’s inMaster of Business Administration from DePaul University. Ms. Wulf provides extensive experience in the food industry in North America, including its fish sector to our Board.



Our Executive Officers



The following table identifies our executive officers who are not members of our Board and sets forth their current positions with us.



David F. Melbourne. Mr. Melbourne was appointed President of AquaBounty in August 2023. He joined AquaBounty in June 2019 as Chief Commercial Officer with a background in general management, operations/commercial management and innovation.  His 25 years of experience in the seafood industry spans both wild fisheries and aquaculture.  He served as Senior Vice President, Consumer Marketing/Government & Industry Relations/Corporate Social Responsibility at Bumble Bee Foods, LLC from 2005 to 2019.



David A. Frank. Mr. Frank was appointed Chief Financial Officer and Treasurer of AquaBounty in October 2007.  Prior to joining AquaBounty, he served as Chief Financial Officer of Magellan Biosciences and President of TekCel between 2003 and 2007.



Angela M. Olsen. Ms. Olsen was appointed General Counsel and Corporate Secretary in November 2019. Prior to joining AquaBounty, she served as Senior Advisor and Associate General Counsel at E.I. du Pont de Nemours and Company (NYSE:DD) between 20172010 and 2019.

Alejandro Rojas. Mr. Rojas joined AquaBounty as the Chief Operating Officer of AquaBounty Farms (our wholly owned subsidiary) in February 2014.



Our executive officers are elected by our Board and hold office until removed by the Board, andor until their successors have been duly elected and qualified or until their earlier resignation, retirement, removal, or death. The principal occupation and employment during the past five years of each of our executive officers was carried on, in each case except as specifically identified above, with a corporation or organization that is not a parent, subsidiary or other affiliate of us. There is no arrangement or understanding between any of our executive officers and any other person or persons pursuant to which they were or are to be selected as an executive officer. There are no material legal proceedings to which any of our executive officers or any associate of any such executive officer is a party adverse to us or any of our subsidiaries or in which any such person has a material interest adverse to us or any of our subsidiaries.



Corporate Governance Principles



We are committed to having sound corporate governance principles. Having such principles is essential to maintaining our integrity in the marketplace. Our Code of Business Conduct and Ethics and the charters for each of the Audit, Compensation and Human Capital, and Nominating and Corporate Governance (“NCG”) Committees are available on the investor relations section of our corporate website (www.aquabounty.com). A copy of our Code of Business Conduct and Ethics and the committee charters may also be obtained upon request to Corporate Secretary, AquaBounty Technologies, Inc., 2 Mill & Main Place,233 Ayer Road, Suite 395, Maynard,4, Harvard, Massachusetts 01754.01451.



Environmental, Social and Governance



Historically, we  have viewed the focus onWe believe Environmental, Social and Governance (“ESG”) concerns as foundational to a well-run business andare fundamental to our Purpose and Values as welland serve as a critical aspect offoundation to how we operate our business, deliver resultsbusiness.  Our focus on ESG has been instrumental in driving continuous improvement and drive continuous improvement.  We embraced ESG early in the development of our business practices, as we see it as a critical component to building our culture, and as a strategic imperative for identifyinghas resulted in increased efficiencies and effectiveness as we grow.  The ESG reporting requirements and norms will continue to evolve and we will continue to monitor those changes.throughout our operations.  We believe that taking ESG considerations into account in our decision-making process ensures a disciplined approach to risk management.

Our ESG Committee, which is comprised of our executive management team, with oversight by our Board of Directors, has worked cross functionally to develop our strategy, structure, processesprocess and the roadmap for the standards that are relevant to our business.

In 2021,  Currently, we took an important step in our corporate governance evolution by committing to deeper understanding of material non-financial matters of our business across ESG aspects. We deployed a rigorous process where we identified and interviewed external advisors/consulting groups that would provide expertise to assist in developing and implementing our ESG initiatives and selected a qualified strategic counsel and partner. We also identified and implemented a digital system platform to track data inputs used for reporting calculations and to ensure we are collecting data and other ESG inputs on a consistent and ongoing basis.

Following a thorough review of the various ESG reporting standards, we selected the SASB Framework as our primary standard, as the accounting metrics for the Food Sector contain topics that are more specific and pertinent to our business model and operations during the current reporting period.  Additionally, our program and reporting incorporate alignment with several applicable GRI metrics and the United Nations Sustainable Development Goals (“UNSDGs”).    In our initial ESG materiality assessment we chosechoose to focus on the ESG aspects of (i) energy and water management; (ii) consumer welfare and employee health and safety; and (iii) diversity and inclusion, humane and considerate animal welfare, and sound governance and oversight structure.

For more information on  Additionally, our ESG efforts, please read our Annual Report on Form 10-K forframework is aligned with a number of the year ended December 31, 2022.United Nations Sustainable Development Goals.



Code of Ethics



Our Board has adopted the Code of Business Conduct and Ethics that applies to all of our employees, officers and directors, including, but not limited to, our Chief Executive Officer and Chief Financial Officer and other executive and senior financial officers. The Code of Business Conduct and Ethics constitutes our “code of ethics” within the meaning of Section 406 of the Sarbanes-Oxley Act and is our “code of conduct” within the meaning of the listing standards of The Nasdaq Stock Market LLC (“Nasdaq”).  Our Code of Business Conduct and Ethics is posted to our website, and we intend to disclose any amendment or waiver of a provision thereof that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing

similar functions, by posting such information on our website (available at www.aquabounty.com) and/or in our public filings with the SEC. During fiscal year ended December 31, 2022,2023, no waivers were granted from any provision of the Code of Business Conduct and Ethics.



Policy on Trading, Pledging and Hedging of Our Common Stock



Certain transactions in our securities (such as purchases and sales of publicly traded put and call options, and short sales) create a heightened compliance risk or could create the appearance of misalignment between management and stockholders. In addition, securities held in a margin account or pledged as collateral may be sold without consent if the owner fails to meet a margin call or defaults on the loan, thus creating the risk that a sale may occur at a time when an officer or director is aware of material, non­publicnon-public information or otherwise is not permitted to trade in Company securities. Our insider trading policy expressly prohibits short sales and

derivative transactions of our stock by our employees, officers and directors, including hedging short sales of our securities and the purchase or sale of puts, calls, or other derivative securities of the Company or any derivative securities that provide the economic equivalent of ownership. To our knowledge, each of our directors and executive officers complied with this policy during 2022.2023.



Stockholder Communications with Directors



Stockholders may communicate with our directors by sending communications to the attention of the ChairmanChair of the Board, the ChairpersonChair of a committee of the Board, or an individual director via U.S. Mail or Expedited Delivery Services to our address at AquaBounty Technologies, Inc., 2 Mill & Main Place,233 Ayer Road, Suite 395, Maynard,4, Harvard, Massachusetts 01754.01451. The Company will forward by U.S. Mail any such communication to the mailing address most recently provided by the Board member identified in the “Attention” line of the communication. All communications must be accompanied by the following information:





Board Composition



Our Charter provides for the appointment toEach director serving on our Board of up to nine directors who areis elected for a one-year term to hold office until the next annual meeting of our stockholders until the election and qualification of his or until removed from office in accordance with our bylaws.her successor, subject to his or her earlier death, disqualification, resignation or removal. The authorized number of directors may be changed by resolution of the Board. The Board has the power to appoint any person as a director to fill a vacancy on the Board.



Board Independence



As required by the Nasdaq listing rules, our Board evaluates the independence of its members at least once annually and at other appropriate times when a change in circumstances could potentially impact the independence or effectiveness of one of our directors.



In February 2023,2024, our Board undertook a review of the composition of our Board and its committees and the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment, and affiliations, including family relationships, our Board has determined each of Mses. St.Clare, Sharps Myers and Sharp, and Messrs. Clothier, Alvarez, Sterling and Stern are eachis an “independent director” as defined under Nasdaq Listing Rule 5605(a)(2).



Board Leadership Structure



Our Board understands that board structures vary greatly among U.S. public corporations, and our Board does not believe that any one leadership structure is more effective at creating long-term stockholder value. Our Board believes that an effective leadership structure could be achieved either by combining or separating the Board Chair and Chief Executive Officer positions, so long as the structure encourages the free and open dialogue of competing views and provides for strong checks and balances. Specifically, the Board believes that, to be effective, the governance structure must balance the powers of the Chief Executive Officer and the independent directors and ensure that the independent directors are fully informed, able to discuss and debate the issues that they deem important, and able to provide effective oversight of management.



Currently, our Board separatescombines the roles of Chief Executive Officer and Board Chair and the latterbut has appointed a Lead Independent Director who is elected by the independent directors. The Lead Independent Director serves as a liaison between the independent directors and the Chief Executive Officer and Board Chair, and leads executive sessions of Board meetings consisting of only the independent directors. The role of President has been assumed by a member of the executive leadership team. Our Board believes that this leadership structure is appropriate for the companyCompany at this time because it allows the Chief Executive OfficerPresident to focus on operating and managing the company.day-to-day operations of the Company. At the same time, the Chief Executive Officer and Board Chair can focus on corporate strategy and leadership of the Board, including calling and presiding over Board meetings and executive sessions of the independent directors, preparing meeting agendas in collaboration with the Chief Executive Officer, serving as a liaison and supplemental channel of communication between

independent directors and the Chief Executive Officer, and serving as a sounding board and advisor to the Chief Executive Officer.Board.  We believe this structure is appropriate given the size of our executive officer team and our growth trajectory in an evolving industry.



Nevertheless, the Board believes that “one size” does not fit all, and the decision of whether to combine or separate the positions of Chief Executive Officer and Board Chair will vary and depend upon our particular circumstances at a given point in time, taking into consideration the depth and breadth of the executive officer team and the composition of the Board.



Board’s Role in Risk Oversight



Our Board is actively engaged in the oversight of the risks we face and consideration of the appropriate responses to those risks. However, our Board delegates certain of such responsibilities to its committees. The Audit Committee is responsible for reviewing with management our company’sCompany’s policies and procedures with respect to risk assessment and risk management, including reviewing certain risks associated with our financial and accounting systems, accounting policies, investment strategies, regulatory compliance, insurance programs, and other matters. The Audit Committee also reviews and comments on a periodic risk assessment performed by management. After the Audit Committee performs its review and comment function, it reports any significant findings to our Board. The Board is responsible for the oversight of our risk management programs and, in performing this function, receives periodic risk assessment and mitigation initiatives for information and approval as necessary.  In addition, under the direction of our Board and certain of its committees, our legal department assists in the oversight of corporate compliance activities. The Compensation and Human Capital Committee also reviews certain risks associated with our overall compensation program for employees to help ensure that the program does not encourage employees to take excessive risks.



Currently, our management team conducts an annual risk assessment that is led by our Chief Compliance Officer and provided to our Board as part of their oversight responsibility.  The process includes input from all executive officers and senior managers with all identified risks reviewed by our Disclosure Committee to ensure that all risks are accurately disclosed in our public filings.  Identified risks, along with mitigation plans are reviewed with our outside advisors and reported to our Board on an annual basis with quarterly updates.



Board Meeting Attendance



During 2022,2023, our Board met six11 times, and each director attended or participated in 75% or more of the aggregate of (i) the total number of meetings of the Board and (ii) the total number of meetings held by all committees of the Board on which such director served. Members of the Board and its committees also consulted informally with management from time to time. Additionally, non-management Board members met in executive sessions without the presence of management periodically during 2022.2023. We do not have a formal policy regarding board members’ attendance at our annual meetings of stockholders but encourage them to do so; all did in 2022.so. Our 2023 annual meeting of stockholders was attended by one member of our Board.



Board Diversity



We strive to have a Board with race, ethnicity and gender diversity that represents our community and brings diverse ideas and backgrounds to the table.



The table below provides the Diversity Matrix for our Board:





Board Committees



Our Board has three standing committees: the Audit Committee (“AC”), the Compensation and Human Capital Committee (“CHCC”), and the NCGNominating and Corporate Governance Committee (“NCGC”), each of which operate pursuant to a written charter adopted by our Board that is available on our corporate website (www.aquabounty.com) under “Investor Relations.”



Audit Committee. Mses. St.Clare, Sharps Myers, Sharp and Mr. Sterling serve as members of our Audit Committee,AC, and Ms. St.Clare serves as its chair. Each member of the Audit CommitteeAC satisfies the special independence standards for such committee established by the SEC and Nasdaq, as applicable. Ms. St.Clare is an “audit committee financial expert,” as that term is defined by the SEC in Item 407(d) of Regulation S-K. Stockholders should understand that this designation is an SEC disclosure requirement relating to Ms. St.Clare’s experience and understanding of certain accounting and auditing matters, which the SEC has stated does not impose on the director so designated any additional duty, obligation, or liability than otherwise is imposed generally by virtue of serving on the Audit CommitteeAC and/or our Board. No Audit CommitteeAC member is permitted to serve on the audit committee of more than two other public companies, unless the Board determines that such simultaneous service would not impair the ability of the Audit CommitteeAC member to effectively serve on our Audit Committee.AC.  Our Audit CommitteeAC is responsible for, among other things, oversight of our independent auditors and the integrity of our financial statements. Our Audit CommitteeAC held sixfour meetings in 2022.2023.



Compensation and Human Capital Committee. Ms. Sharps Myers and Messrs. Alvarez and Sterling serve as members of our Compensation and Human Capital Committee,CHCC, and Ms. Sharps Myers serves as its chair. Our Compensation and Human Capital CommitteeCHCC is responsible for, among other things, establishing and administering our policies, programs, and procedures for compensating our executive officers and Board. The Compensation and Human Capital CommitteeCHCC may only delegate its authority to subcommittees of its members. None of the members of our Compensation and Human Capital CommitteeCHCC is an officer or employee of our Company. None of our executive officers currently serves, or in the past year has served, as a member of the Boardboard of directors or compensation committee of any entity that has one or more executive officers serving on our Board or Compensation and Human Capital Committee.CHCC. Our Compensation and Human Capital CommitteeCHCC held fivefour meetings in 2022.2023.



Nominating and Corporate Governance Committee. Messrs. Alvarez and Stern, and Ms. St.Clare serve as members of our NCG CommitteeNCGC, and Mr. Alvarez serves as its chair. Our NCG CommitteeNCGC is responsible for, among other things, evaluating new director candidates and incumbent directors and recommending directors to serve as members of our Board committees. Our NCG CommitteeNCGC held sevenfour meetings in 2022.2023.



Director Nominees 



Our Board believes that the Board should be composed of individuals with varied, complementary backgrounds who have exhibited proven leadership capabilities within their chosen fields. Directors should have the ability to quickly grasp complex principles of business and finance, particularly those related to our industry. Directors should possess the highest personal and professional ethics, integrity, and values and should be committed to representing the long-term interests of our stockholders. When considering a candidate for director, the NCG CommitteeNCGC will take into account a number of factors, including, without limitation, the following: depth of understanding of our industry; education and professional background; judgment, skill, integrity, and reputation; existing commitments to other businesses as a director, executive, or owner; personal conflicts of interest, if any; diversity; and the size and composition of the existing Board. Although the Board does not have a policy with respect to consideration of diversity in identifying director nominees, among the many other factors considered by the NCG CommitteeNCGC are the benefits of diversity in boardBoard composition, including with respect to age, gender, race, and specialized background. When seeking candidates for director, the NCG CommitteeNCGC may solicit suggestions from incumbent directors, management, stockholders, and others. Additionally, the NCG CommitteeNCGC may use the services of third-party search firms to assist in the identification of appropriate candidates. During 2022,2023, no director search fees were approximately $88,000 relating to the searches that led to the appointments of Erin Sharp and Michael Stern.incurred. The NCG CommitteeNCGC will also evaluate the qualifications of all candidates properly nominated by stockholders, in the same manner and using the same criteria. A stockholder desiring to nominate a person for election to the Board must comply with the stock holding and advance notice procedures of our Amended and Restated Bylaws, as described in the proxy statement under the heading “Stockholder Proposals for 20242025 Annual Meeting.”



Director Compensation



We believe that the compensation we provide to our Board is both competitive and in line with that provided to boards of directors of similar companies in our industry. We planFrom time to time, the Board will conduct a market assessment of director compensation.

For fiscal year 2023, the previous Board Chair received prorated annual compensation inof $26,658 until his retirement on May 25, 2023.



For fiscal year 2022, the Chairman of our Board received annual compensation of £50,000 (approximately $60,450 using the pound sterling to U.S. Dollar spot exchange rate of 1.209 published in The Wall Street Journal as of December 31, 2022), payable in four quarterly installments. He also received an annual grant of restricted shares of our Common Stock valued at £20,000 (approximately $26,144 based on the fair market value on the date of grant), which vest in three tranches over two years.

For fiscal year 2022,2023, all non-employee directors received an annual cash retainer of $40,000, (prorated for time of service), payable in four quarterly installments. The Chair of the Audit CommitteeAC received an additional $25,000, the Chair of the Compensation and Human Capital CommitteeCHCC and the Chair of the NCG CommitteeNCGC each received an additional $15,000, and members of a board committee received an additional $5,000 (prorated for time of service).each committee on which they served. All additional cash payments are paid in four quarterly installments.  All non-employee directors received an annual grant of options to purchase 2,500125 shares of our Common Stock (with an exercise price equal to the fair market value on the date of grant), with vesting daily over one year.  In addition, Ms. Sharps Myers receivedthrough the date of the next annual meeting and a grant of options to purchase 1,486 shares$20,000 of our Common Stock for prorated service during 2021.restricted share units that vest at the date of the next annual meeting.



The following table discloses all compensation provided to the non-employee directors for the most recently completed fiscal year ended December 31, 2022:2023:

Director Summary Compensation Table



The following table provides the aggregate outstanding equity awards held by each non-employee director as of December 31, 2022.

Vote Required

The election of our directors requires a plurality vote.  Director nominees are nominated to serve on our Board for a one-year term, to hold office until the next annual meeting of our stockholders or until the election and qualification of his or her successor and subject to his or her earlier death, disqualification, resignation or removal.  Each nominee must receive at least one FOR vote and nominees receiving the highest number of FOR votes are elected.  If nominees are unopposed, election requires only a single vote or more.

PROPOSAL 2:

RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Our Board recommends that stockholders vote FOR the ratification of the

appointment of Deloitte & TOUCHE LLP to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2023.

The Audit Committee of the Board has appointed the firm of Deloitte & Touche LLP (“Deloitte”) to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2023, and is asking the stockholders to ratify this appointment.

The Audit Committee believes that the retention of Deloitte for the 2023 fiscal year is in the best interest of us and our stockholders. One or more representatives of Deloitte are expected to be present at the Annual Meeting with the opportunity to make a statement if they so desire and to be available to respond to appropriate questions.

In the event the stockholders fail to ratify the appointment of Deloitte as our independent registered public accounting firm, the Audit Committee may reconsider its selection.

Principal Accountant Fees and Services

The following table summarizes the fees billed by Deloitte for the fiscal years ended December 31, 2022 and 2021:

Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services

Under its charter, the Audit Committee must pre-approve all engagements of our independent registered public accounting firm, unless an exception to such pre-approval exists under the Exchange Act or the rules of the SEC. The Audit Committee has delegated to its Chair the authority to evaluate and approve service engagements on behalf of the full Audit Committee in the event a need arises for specific pre-approval between Audit Committee meetings. All of the audit, audit-related, tax services, and all other services provided by our independent registered public accounting firm for the 2022 fiscal year were approved by the Audit Committee in accordance with the foregoing procedures.

Vote Required

The election of our directors requires a plurality vote.  Director nominees are nominated to serve on our Board for a one-year term, to hold office until the next annual meeting of our stockholders or until the election and qualification of his or her successor and subject to his or her earlier death, disqualification, resignation or removal.  Each nominee must receive at least one FOR vote, and the seven nominees receiving the highest number of FOR votes are elected.  In an uncontested election, where the number of nominees and available board seats are equal, election requires only a single vote or more.

PROPOSAL 2:

RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Our Board recommends that stockholders vote FOR the ratification of the

appointment of Deloitte & TOUCHE LLP to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

The Audit Committee (“AC”) of the Board has appointed the firm of Deloitte & Touche LLP (“Deloitte”) to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2024, and is asking the stockholders to ratify this appointment.

The AC believes that the retention of Deloitte for the 2024 fiscal year is in the best interest of us and our stockholders. One or more representatives of Deloitte are expected to be present at the Annual Meeting with the opportunity to make a statement if they so desire and to be available to respond to appropriate questions.

In the event the stockholders fail to ratify the appointment of Deloitte as our independent registered public accounting firm, the AC may reconsider its selection.

Principal Accountant Fees and Services

The following table summarizes the fees billed by Deloitte for the fiscal years ended December 31, 2023 and 2022:

Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services

Under its charter, the AC must pre-approve all engagements of our independent registered public accounting firm, unless an exception to such pre-approval exists under the Exchange Act or the rules of the SEC. The AC has delegated to its Chair the authority to evaluate and approve service engagements on behalf of the full AC in the event a need arises for specific pre-approval between AC meetings. All of the audit, audit-related, and tax services provided by our independent registered public accounting firm for the 2023 fiscal year were approved by the AC in accordance with the foregoing procedures.

Vote Required



The affirmative vote of the holders of a majority of the shares of our Common Stock representedpresent in person or represented by proxy at the annual meeting and entitled to vote on the matter and which has been voted is required to ratify the appointment of Deloitte to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2023.2024.







PROPOSAL 3:3:  

APPROVAL OF AN AMENDMENT TO OUR 2016 EQUITY INCENTIVE PLAN, AS AMENDED

Our Board recommends that the stockholders vote FOR the approval of the Plan Amendment, to increase the number of authorized shares of Common Stock available for issuance under the 2016 EIP to 4,300,000 and to require stockholder approval for the repricing or CASH BUYOUT of outstanding awards.

Introduction

Our 2016 Equity Incentive Plan, adopted on March 11, 2016, and amended on April 30, 2019 and on April 28, 2020, currently authorizes us to issue a total of 1,900,000 shares of Common Stock. On February 28, 2023, our Board determined that the number of shares of Common Stock available for issuance under the 2016 EIP was insufficient to continue to attract, retain, and motivate our employees, consultants, and directors using equity compensation. Subject to stockholder approval, the Board therefore unanimously approved an amendment to the 2016 EIP (i) to increase the number of shares of Common Stock authorized for issuance under the 2016 EIP from 1,900,000 shares to 4,300,000 shares and (ii)  to require stockholder approval for the repricing of outstanding awards or the cash buyout of outstanding awards (“Plan Amendment”). In accordance with the General Corporation Law of the State of Delaware, we are hereby seeking approval of the 2016 EIP, as further amended by the Plan Amendment, by our stockholders.

The proposed Plan Amendment would delete Section 3(a) of the 2016 EIP and replace it with the following text:

Further, the proposed Plan Amendment would delete Section 2(b)(xi) of the 2016 EIP and replace it with the following text:

No other changes to the 2016 EIP are being proposed, and the Plan Amendment would not modify the number of shares held by, or the rights of, existing stockholders or participants in the 2016 EIP.

Reasons for the Share Increase

Equity awards have been historically and, we believe, will continue to be, an integral component of our overall compensation program for our employees, directors, and consultants. Approval of the Plan Amendment will allow us to continue to grant equity awards at levels we determine to be appropriate in order to attract new employees and directors, retain our existing employees and directors, and provide incentives for such persons to exert maximum efforts for our success. The 2016 EIP allows us to continue to utilize a broad array of equity incentives with flexibility in designing equity incentives, including stock option grants, stock appreciation rights, stock awards, and stock unit awards.

We believe it is critical for our long-term success that the interests of our employees and directors are tied to our success as “owners” of our business. The equity incentive programs we have in place are intended to build stockholder value by attracting and retaining talented employees and directors. We believe that we must continue to offer competitive equity compensation packages in order to retain and motivate the talent necessary for our continued growth and success. We carefully monitor the equity compensation and equity holdings of our employees, directors, and consultants, as well as the type of equity awards we grant, to ensure that these awards continue to provide incentives for the recipients to work toward our success.

The following table sets forth the number of shares remaining available for future awards under the 2016 EIP as of March 31, 2023:

We have and we expect to continue to experience growth in personnel as we progress our business. An increase in the share reserve to 4,300,000 units would be equivalent to approximately 6% of our outstanding shares as of March 31, 2023.  This is consistent with the ratio of the share reserve to outstanding shares when it was last increased in 2020 to 1,900,000 units. If our stockholders do not approve the Plan Amendment, we believe that we will be unable to successfully use equity as part of our compensation program, as most biotech companies do, putting us at a significant disadvantage. The Board believes that, if the Plan Amendment is approved, the increase in the share reserve will leave sufficient reserves of authorized but unissued shares (i.e.,  2,400,533 shares of Common Stock) for the purpose of future equity grants under the 2016 EIP for the next three years. Therefore, we believe that approval of this request is in the best interest of our stockholders and our company.

Based solely on the closing price of our common stock as reported by NASDAQ on March 31, 2023, and the maximum number of shares that would have been available for awards as of such date under the 2016 EIP (taking into account the increase contemplated by the Plan Amendment), the maximum aggregate market value of the common stock that could potentially be issued under the 2016 EIP is $1.44 million.  The table below shows the number of awards granted under the 2016 EIP for the past three years.

Key Features Designed to Protect Stockholders’ Interests

The design of the 2016 EIP, as amended by the Plan Amendment, reflects our commitment to corporate governance and the desire to preserve stockholder value as demonstrated by the following features:

Summary of the 2016 Equity Incentive Plan

The following summary of the material provisions of the 2016 EIP, as further amended by the Plan Amendment, is not intended to be

exhaustive and is qualified in its entirety by the terms of the 2016 EIP, which is included as Exhibit 10.6 to the Company’s Registration Statement on Form 10 filed on November 7, 2016; the terms of the 2019 amendment to the 2016 EIP, which is included as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on May 2, 2019;  the terms of the 2020 amendment to the 2016 EIP, which is included as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on April 29, 2020 and the terms of the Plan Amendment, a copy of which is set forth as Appendix A hereto.

Shares Available Under the 2016 EIP. The 2016 EIP, as further amended by the Plan Amendment, has a maximum share reserve of 4,300,000 shares of our common stock, subject to the permitted adjustments as explained below. Shares will return to the 2016 EIP, and will not reduce the number of shares available for issuance under the 2016 EIP, if the award: (1) expires or otherwise terminates without all of the shares covered by such award having been issued; (2) is settled in cash (i.e., the participant receives cash rather than stock); (3) is forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required to vest such shares in the participant; or (4) is reacquired by the Company in satisfaction of tax withholding obligations or as consideration for the exercise or purchase price of an award.

Administration. The 2016 EIP provides that the Board or a duly authorized committee thereof may administer the 2016 EIP (in such capacity, the “Administrator”). One or more of our officers may be empowered to designate employees to receive awards under the 2016 EIP and determine the size of any such awards (subject to certain limitations described in the 2016 EIP).    The Administrator determines which persons will receive awards, the number of shares subject to such awards, and the material terms and conditions of those awards, including the vesting, exercise, and delivery schedule for shares acquired under the awards. In addition, the Administrator may undertake an action that is treated as a repricing under generally accepted accounting principles, including reducing the exercise price to the then-current fair market value or canceling an outstanding underwater option in exchange for a new award or a cash payment,  but only to the extent such action is approved by stockholders. The Company will document these awards using forms approved by the 2016 EIP administrator. We may grant multiple awards to any participant, even if previously granted awards remain outstanding. The decisions of the Administrator are final and binding.

Eligibility. We may grant awards under the 2016 EIP to the officers, employees, directors, and consultants of the Company and its subsidiaries. As of March 31, 2023, approximately 107 individuals would have been eligible to participate in the Plan had it been effective on such date, which includes 8 executive officers, 92 employees who are not executive officers, 7 non- employee directors and 0 consultants.

Permitted Awards. Under the 2016 EIP, we may grant stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, and other awards whose value is determined by reference to shares of our common stock.

Stock Options. A stock option is the right to purchase shares of common stock at a price not less than the fair market value per share at the date of grant (except to the extent permitted by the U.S. Internal Revenue Code (the “Code”) in connection with the assumption of or substitution of an option for another option or stock appreciation right in connection with a change in control). No stock option may be exercisable more than ten years from the date of grant. Each grant will specify the period of continuous service with us or any subsidiary that is necessary before the stock options become exercisable. The aggregate number of shares of our common stock actually issued or transferred on the exercise of incentive stock options will not exceed 8,600,000 shares of our common stock.

SARs. An SAR is a right to receive the appreciation distribution payable on the exercise of the SAR in an amount not greater than the excess of (i) the fair market value of the share of vested common stock subject to such award on the date of the exercise of the SAR over (ii) the strike price. SARs may be settled in cash, in shares of common stock, or in any combination of the two. The strike price for an SAR is generally not less than the fair market value per share at the date of grant (except to the extent permitted by the Code in connection with the assumption of or substitution of an option for another option or stock appreciation right in connection with a change in control).

Restricted Stock. A grant of restricted stock involves the transfer by us to a participant of ownership of a specific number of shares of common stock in consideration of the performance of services. A holder of restricted stock has voting, dividend, and other ownership rights in such shares. The transfer may be made without additional consideration or in consideration of a purchase price determined by the Administrator. Any dividends or other distributions paid with respect to unvested restricted stock will generally be subject to the same restrictions and risk of forfeiture as the underlying award.

RSUs. A grant of RSUs is the right to receive shares of common stock in the future, subject to any restrictions specified by the 2016 EIP administrator. During the restriction period and until shares are actually issued, the participant will have no rights of ownership in the shares of common stock. The Administrator may authorize the payment of dividend equivalents on RSUs, generally subject to the same restrictions and risk of forfeiture that apply to the underlying award.

Other Awards. The Administrator may, subject to limitations under applicable law, grant to any participant such other awards that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on, or related to, shares of common stock.

Amendments. We may amend the 2016 EIP from time to time. If required by the rules of Nasdaq (or any other applicable securities exchange), we will seek stockholder approval of any Plan amendment that (i) would materially increase the benefits accruing to participants under the 2016 EIP, (ii) would materially increase the number of securities that may be issued under the 2016 EIP, (iii) would materially expand the class of participants under the 2016 EIP, or (iv) must otherwise be approved by our stockholders to comply with applicable law or the rules of Nasdaq (or such other securities exchange), including an amendment to permit repricing of outstanding awards or a cash buy-out of outstanding awards.

Transferability. Except as otherwise determined by the Administrator, awards are generally not transferable by the participant except by will or the laws of descent and distribution. In no event may any award granted under the 2016 EIP be transferred for value.

Adjustments. In the event of a change in our common stock without the receipt of consideration by the Company through a merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or any similar equity restructuring transaction, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the 2016 EIP as the share reserve, (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of incentive stock options, and (iii) the class(es) and number of securities and price per share subject to outstanding awards. The Board will make such adjustments, and its determination will be final, binding, and conclusive.

Change in Control. If we are subject to a change in control, the Administrator may: (i) arrange for the surviving corporation or acquiring corporation to assume or continue the award or to substitute a similar stock award (including, but not limited to, an award to acquire the same consideration paid to the stockholders of the Company in the transaction); (ii) arrange for the assignment of any reacquisition or repurchase rights held by the Company in respect of the award to the surviving corporation or acquiring corporation; (iii) accelerate the vesting, in whole or in part, of the award (and, if applicable, exercisability), with the award terminating if not exercised (if applicable) immediately prior to the effective time; (iv) arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the award; (iv) cancel or arrange for the cancellation of the award, to the extent not vested or not exercised, in exchange for such cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; or (v) make a payment equal to the excess, if any, of (A) the value of the property the holder would have received on the exercise of the award immediately prior to the transaction over (B) any exercise price payable in connection with such exercise. For clarity, this payment may be zero if the fair market value of the property is equal to or less than the exercise price. The Board need not take the same action or actions with respect to all awards or portions thereof or with respect to all participants.

Claw-Back Provisions. All awards granted under the 2016 EIP will be subject to recoupment in accordance with any clawback policy that the Company adopts or is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise required by applicable law (e.g., the Dodd- Frank Wall Street Reform and Consumer Protection Act). In addition, the Board may impose such other clawback, recovery, or recoupment provisions in an award agreement as the Board determines necessary or appropriate, including, but not limited to, a reacquisition right in respect of previously acquired shares of or other cash or property on the occurrence of cause.

Effective Date and Termination. The 2016 EIP became effective as of March 11, 2016 (the “Effective Date”). No grant will be made under the 2016 EIP after March 11, 2026, the tenth anniversary of the Effective Date. All grants made on or prior to such date will continue in effect thereafter subject to the terms of the applicable award agreement and the terms of the 2016 EIP.

New Plan Benefits

Because the grant of awards under the 2016 EIP is within the discretion of the Administrator, the Company cannot determine the dollar value or number of shares of common stock that will in the future be received by or allocated to any participant in the 2016 EIP. Accordingly, in lieu of providing information regarding benefits that will be received under the 2016 EIP, the following table provides information concerning the benefits that were received by the following persons and groups during 2022 under the 2016 EIP: each named executive officer (as listed in the Summary Compensation Table, which appears later in this proxy statement); all current executive officers, as a group; all current directors who are not executive officers, as a group; and all current employees who are not executive officers, as a group.

Tax Aspects Under the Code

The following is a summary of the principal federal income tax consequences of certain transactions under the 2016 EIP. It does not describe all federal tax consequences under the 2016 EIP, nor does it describe state or local tax consequences.

Incentive Options. No taxable income is generally realized by the optionee upon the grant or exercise of an incentive option. If shares of common stock issued to an optionee pursuant to the exercise of an incentive option are sold or transferred after two years from the date of grant and after one year from the date of exercise, then (i) upon sale of such shares, any amount realized in excess of the option price (the amount paid for the shares) will be taxed to the optionee as a long-term capital gain, and any loss sustained will be a long-term capital loss, and (ii) the Company will not be entitled to any deduction for federal income tax purposes. The exercise of an incentive option will give rise to an item of tax preference that may result in alternative minimum tax liability for the optionee.

If shares of common stock acquired upon the exercise of an incentive option are disposed of prior to the expiration of the two-year and one-year holding periods described above (a “disqualifying disposition”), generally (i) the optionee will realize ordinary income in the year of disposition in an amount equal to the excess (if any) of the fair market value of the shares of common stock at exercise (or, if less, the amount realized on a sale of such shares of common stock) over the option price thereof, and (ii) we will be entitled to deduct such amount. Special rules will apply where all or a portion of the exercise price of the incentive option is paid by tendering shares of common stock.

If an incentive option is exercised at a time when it no longer qualifies for the tax treatment described above, the option is treated as a non-qualified option. Generally, an incentive option will not be eligible for the tax treatment described above if it is exercised more than three months following termination of employment (or one year in the case of termination of employment by reason of disability). In the case of termination of employment by reason of death, the three-month rule does not apply.

Non-Qualified Options. No income is realized by the optionee at the time a non-qualified option is granted. Generally (i) at exercise, ordinary income is realized by the optionee in an amount equal to the difference between the option price and the fair market value of the shares of common stock on the date of exercise, and we receive a tax deduction for the same amount, and (ii) at disposition, appreciation or depreciation after the date of exercise is treated as either short-term or long-term capital gain or loss depending on how long the shares of common stock have been held. Special rules will apply where all or a portion of the exercise price of the non-qualified option is paid by tendering shares of common stock. Upon exercise, the optionee will also be subject to Social Security taxes on the excess of the fair market value over the exercise price of the option.

Other Awards. The Company generally will be entitled to a tax deduction in connection with other awards under the 2016 EIP in an amount equal to the ordinary income realized by the participant at the time the participant recognizes such income.

Participants typically are subject to income tax and recognize such tax at the time that an award is exercised, vests, or becomes non- forfeitable, unless the award provides for a further deferral.

Parachute Payments. The vesting of any portion of an award that is accelerated due to the occurrence of a change in control (such as a sale event) may cause a portion of the payments with respect to such accelerated awards to be treated as “parachute payments” as defined in the Code. Any such parachute payments may be non-deductible to the Company, in whole or in part, and may subject the recipient to a non-deductible 20% federal excise tax on all or a portion of such payment (in addition to other taxes ordinarily payable).

Effectiveness of the Plan Amendment

If the Plan Amendment is approved by our stockholders, they will become effective immediately. If the Plan Amendment is not approved, the 2016 EIP would remain unchanged, and the number of authorized shares of Common Stock issuable under the 2016 EIP would remain 1,900,000. Other than as described herein, this proposed Plan Amendment effects no other changes to the 2016 EIP.

Vote Required

The affirmative vote of holders of a majority of the shares of our Common Stock represented in person or by proxy at the annual meeting and entitled to vote on the matter is required to approve the Plan Amendment, to increase the number of authorized shares of Common Stock reserved for issuance under the 2016 EIP to 4,300,000 and to require stockholder approval for the repricing or buy-back of outstanding awards.

PROPOSAL 4:  

NON-BINDING, ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS

Our Board recommends a vote FOR the approval, on a non-binding, advisory basis, of THE COMPENSATION OF our named executive officer compensationofficerS as disclosed in this proxy statement.



As required by Section 14A of the Exchange Act, we are asking our stockholders to vote to approve, on a non-binding, advisory basis, not less frequently than once every three years, the compensation of our named executive officers as disclosed in this proxy statement.



As described in detail under the heading “Executive Compensation, and Other Information,” we seek to closely align the interests of our named executive officers with the interests of our stockholders. Our compensation programs are designed to reward our named executive officers for the achievement of short-term and long-term strategic goals, while at the same time avoiding the encouragement of unnecessary or excessive risk-taking.



Stockholders are urged to read the “Executive Compensation and Other Information”Compensation” section of this proxy statement, which discussdiscusses how our executive compensation policies and procedures implement our compensation philosophy and contain tabular information and narrative discussion about the compensation of our named executive officers. Our Board and the Compensation and Human Capital Committee believe that these policies and procedures are effective in implementing our compensation philosophy and in achieving our compensation program goals.



The vote on this resolution is not intended to address any specific element of compensation but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy statement. The vote is advisory, which means that the vote is not binding on us, our Board or the Compensation and Human Capital Committee. As such, the results of the vote will not be construed to create or imply any change to the fiduciary duties of our Board. Although non-binding, the Board and the Compensation and Human Capital Committee value the opinions that stockholders express in their votes and will review the voting results and take them into consideration as they deem appropriate when making future decisions regarding our executive compensation program.



At our 2023 annual meeting of stockholders, our stockholders supported, on an advisory basis, the Board’s proposal that the say-on-pay advisory vote occur on an annual basis. Although annual say-on-pay advisory votes are not required by our bylaws, the Board currently believes that having our stockholders provide annual feedback on our compensation practices supports effective governance. As a result, and in light of the overwhelming support of our stockholders, the next say-on-pay advisory vote is expected to occur in 2025.

Accordingly, we are asking our stockholders to vote FOR the following resolution:



“RESOLVED, that the compensation paid to the Named Executive Officers of AquaBounty Technologies, Inc., as disclosed in this proxy statement pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion, is hereby approved on a non-binding, advisory basis.”



Vote Required

The approval of this non-binding, advisory proposal requires the affirmative vote of the holders of a majority of the shares of our Common Stock representedpresent in person or by proxy at the annual meeting and entitled to vote on the matter.

PROPOSAL 5:

NON-BINDING, ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS

Our Board recommends a vote of 1 YEAR for the frequency of future non-binding advisory votes on our named executive officers' compensation.

As required by Section 14A of the Exchange Act, we are providing our stockholders with the opportunity to cast a non-binding advisory vote on how frequently we will hold a non-binding vote on our named executive officers’ compensation. We are required to solicit stockholder votes on the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers at least once every six years, although we may seek stockholder input more frequently. By voting with respect to this proposal, stockholders may indicate whether they would prefer that we conduct future non-binding advisory votes to approve the compensation of our named executive officers every one, two or three years. Stockholders also may, if they wish, abstain from casting a vote on this proposal. Our Board has determined that an annual non-binding advisory vote to approve the compensation of our named executive officers will allow our stockholders to provide timely and direct input on our executive compensation philosophy, policies and practices as disclosed in the proxy statement each year. Our Board believes that an annual vote is therefore consistent with our efforts to engage in an ongoing dialogue with our stockholders on executive compensation and corporate governance matters.

Accordingly, we are asking our stockholders to vote on the following resolution at the Annual Meeting:

RESOLVED, that the stockholders of AquaBounty Technologies, Inc. approve, on a non-binding advisory basis, the submission by the Company of a non-binding, advisory say-on-pay resolution pursuant to Section 14A of the Exchange Act every:

•  one year;

• two years; or

• three years.

We recognize that our stockholders may have different views as to the best approach, and therefore we look forward to hearing from our stockholders as to their preferences on the frequency of an advisory vote on executive compensation. This vote is advisory and not binding on us or our Board. As such, the results of the vote will not be construed to create or imply any change to the fiduciary duties of our Board. Although non-binding, the Board and the compensation committee value the opinions that stockholders express in their votes and will review the voting results and take them into consideration when making future decisions regarding the frequency of future advisory votes on the compensation of our named executive officers.

Vote Required

Stockholders will not be voting to approve or disapprove of the recommendation of our Board, but are instead asked to indicate their preferences, on an advisory basis, as to whether the non-binding advisory vote on the approval of the Company’s executive officer compensation practices should be held every year, every other year or every three years. The proxy card provides stockholders with the opportunity to choose among four options with respect to this proposal (holding the vote every 1 YEAR, 2 YEARS, or 3 YEARS, or ABSTAIN from voting). The option among those choices that receives the affirmative vote of holders of a majority (or if a majority is not reached, the option that receives the most votes) of the shares of our Common Stock represented in person or by proxy at the annual meeting and entitled to vote on the matter will be deemed to be the frequency preferred by the stockholders.  Our Board values the opinions of the stockholders in this matter, and our Board intends to hold say-on-pay votes in the future in accordance with the frequency preferred by the stockholders.which has been voted.









OTHER MATTERS



We do not know of any matters to be presented at the 20232024 annual meeting of stockholders other than those mentioned in this proxy statement. If any other matters properly come before the annual meeting, it is the intention of the persons named in the enclosed form of proxy to vote the shares they represent as our Board recommends.

OWNERSHIP OF SECURITIES



The following table sets forth certain information known to us with respect to the beneficial ownership of our Common Stock as of March 31, 2023,2024, by (i) each person who, to our knowledge, beneficially owns 5% or more of the outstanding shares of our Common Stock, (ii) each of our directors, (iii) each named executive officer (as listed in the Summary Compensation Table, which appears later in this proxy statement), and (iv) all current directors and executive officers as a group. None of the shares reported as beneficially owned by our directors or executive officers are currently pledged as security for any outstanding loan or indebtedness.



We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws. The table lists applicable percentage ownership based on 71,338,9383,857,444 shares of our Common Stock outstanding as of March 31, 2023.2024. The number of shares beneficially owned includes shares of our Common Stock that each person has the right to acquire within 60 days of March 31, 2023,2024, including upon the vesting of stock awards and the exercise of stock options or warrants.options. These stock optionsawards and warrantsoptions are deemed outstanding for the purpose of computing the percentage of outstanding shares of our Common Stock owned by such person but are not deemed outstanding for the purpose of computing the percentage of outstanding shares of our Common Stock owned by any other person.





*Indicates beneficial ownership of less than one percent of the total outstanding shares of our Common Stock.

(1) Unless otherwise indicated, the address for each beneficial owner is c/o AquaBounty Technologies, Inc., 2 Mill & Main Place,233 Ayer Road, Suite 395, Maynard,4, Harvard, MA 01754.01451.

(2) Based solely on a Schedule 13D/A filed on November 24, 2021, by Randal J. Kirk and Third Security, LLC (“Third Security” and such filing, the “TS Schedule 13D/A”).  Third Security has sole voting and dispositive power with respect to 1,580,954Beneficial ownership includes shares of Common Stock to be issued pursuant to the vesting of outstanding stock awards and Mr. Kirk and entities controlled by him, other than Third Security,  have sole voting and dispositive power with respect to 3,756,711 sharesCommon Stock issuable upon the exercise of Common Stock.    Shares beneficially owned excludes shares underlying expired stock options previously held by Mr. Kirk’s spouse and reported in the TS Schedule 13D/A, but includes 2,665 shareswithin 60 days of Common Stock reported to us as held by Mr. Kirk’s spouse.

(3) Beneficial ownership includes:March 31, 2024:





EQUITY COMPENSATION PLAN INFORMATION

The following table provides information as of December 31, 2023, with respect to the shares of our common stock that may be issued under our existing equity compensation plans:

EXECUTIVE COMPENSATION



We are a “smaller reporting company” under SEC rules, and as such, we are not required to include a Compensation Discussion and Analysis section in this proxy statement and have elected to comply with the reduced disclosure requirements applicable to smaller reporting companies. We are evaluating the need for revisions to our executive compensation program to ensure our program is competitive with those of the companies with which we compete for executive talent and is appropriate for a public company.



Named Executive Officers



The tables and discussion below present compensation information for our chief executive officer and our two other most highly compensated officers for the year ended December 31, 20222023 (“fiscal year 2022”2023”);, all of whom we refer to collectively as our named executive officers. These officers are:





Summary Compensation Table



The following table provides certain summary information concerning the compensation paid to our named executive officers in the fiscal years ended December 31, 20222023 and 2021.2022.



As of December 31, 2022, we paid base salaries to Ms. Wulf, Mr. Frank, and Ms. Olsen of $412,000, $301,156, and $302,357, respectively. As of December 31, 2021,2023, the base salaries of Ms. Wulf, Mr. Melbourne and Mr. Frank were $432,600, $375,000, and $325,000, respectively. As of December 31, 2022, the base salaries of Ms. OlsenWulf, Mr. Melbourne and Mr. Frank were $400,000, $292,384,$412,000, $300,000, and $293,550,$301,156, respectively. Base salaries are used to recognize the experience, skills, knowledge, and responsibilities required of all of our employees, including our named executive officers. Certain of our named executive officers are currently party to an employment agreement that provides for the continuation of certain compensation upon termination of employment. See “-Employment Agreements.”



Our Board may, at its discretion, award bonuses toFor 2023, each of our named executive officers from timewas eligible to time. We typically establishearn an annual cash bonus targetsto compensate them for attaining short-term Company and individual goals as approved by our Board.  For 2023, bonuses were determined based on attaining strategic and financial Company goals, weighted 70% in the aggregate, and individual goals, weighted 30%. The 2023 target bonuses for each of Ms. Wulf and Messrs. Melbourne and Frank were 50%, 40% and 40%, respectively, of his or her annual base salary.  Each individual’s respective target bonus was set by the Board. The actual annual cash bonuses awarded to the named executive officers and evaluate theirfor 2023 performance, based onas determined by our Board, are set forth above in the achievement of specified company and individual goals and objectives. Our management may propose bonus awards to2023 Summary Compensation Table in the Compensation and Human Capital Committee of the Board primarily based on such achievements.column titled “Non-Equity Incentive Plan Compensation.” Our Board makes the final determination of the eligibility requirements for and the amounts of such bonus awards.

Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive officers, or any formal equity ownership guidelines applicable to them, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture, and help to align the ownership interests of our executives and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes our executive officers to remain in our employment during the vesting period. Compensation decisions for the officers other than the CEO are made by the CHCC in consultation with the CEO.



Outstanding Equity Awards at Fiscal Year End



The following table provides certain summary information concerning outstanding equity awards held by our named executive officers as of December 31, 2022.2023.



Pay Versus Performance



As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are providing information about the relationship between executive compensation actually paid to our principal executive officer (PEO)(“PEO”) and the other named executive officers (NEOs)(“NEOs”), as calculated in accordance with Item 402(v) of Regulation S-K, and certain financial performance measures.



Pay Versus Performance Table





In accordance with the requirements of Item 402(v) of Regulation S-K, the adjustments made to derive compensation actually paid to our PEO and non-PEO NEOs are contained in the following table:

Description of the Relationship Between Compensation Actually Paid and Selected Performance Metric



We believe it is critical for our long-term performance that the compensation program for our executive officers is structured to attract, retain and motivate the talent necessary for our continued growth and success.  The compensation for our PEO and NEOs includes salary, non-equity incentives and stock and option awards.  The equity incentive programs we have in place are intended to build stockholder value by tying the interests of our executive officers to the success of the Company as “owners” of our business.  The charts below depict the relationship between the executive compensation actually paid to our PEO and our non-PEO NEOs and our net income and the value of an initial fixed $100 investment based on Total Shareholder Return (“TSR”) for the three-year period of 20202021 through 2022.2023.



Employment Agreements



We have entered into employment agreements with each of Ms. Wulf, Mr. Frank and Ms. Olsen.Messrs. Melbourne and Frank. Each agreement provides for the payment of a base salary; an annual bonus opportunity based on a percentage of the executive’s salary, with any bonus payout determined at the discretion of our Board based on achievement of financial targets and other performance criteria; and certain other forms of benefits and compensation. Ms. Wulf’s agreement also included a one-time grant of an option to purchase 150,000 shares of our Common Stock and restricted shares of our Common Stock worth $350,000. Ms. Olsen’s agreement included a one-time cash bonus of $28,500, a one-time option grant to purchase 35,000 shares of our Common Stock and restricted shares of our Common Stock worth $70,000. In addition, under each agreement, we may terminate the employee’s employment without notice or payment at any time for cause.



Sylvia Wulf

TheEach employment agreement with Ms. Wulf will remainremains in effect unless and until terminated in accordance with the terms and conditions set forth in the agreement. Ms. Wulf’sEach agreement provides that employment may be terminated by either us or Ms. Wulfthe individual with no less than thirty days’ notice to the other party. If Ms. Wulf’sthe individual’s employment is terminated by us without cause or by herthe individual for good

reason, as those terms are defined in herthe employment agreement, Ms. Wulfthe individual would be paid one year of continued base salary, starting on the date of termination and a prorated earned bonus payment. In addition, if such termination occurs within 12 months following the occurrence of a change in control (as such term is defined in herthe employment agreement), Ms. Wulf’sthe agreement also provides for 100% acceleration of her stock option and restricted share grants. Receipt of the severance payments and benefits described above is subject to the individual’s execution of a release of claims and continued compliance with a non-disparagement covenant. Under each agreement, we may terminate the individual’s employment without notice or payment at any time for cause.



David Frank

Mr. Frank’s agreement provides that employment may be terminated by either us or Mr. Frank. If Mr. Frank’s employment is terminated by us without cause, as those terms are defined in his employment agreement, Mr. Frank would be paid one year of continued base salary and benefits, starting on the date of termination and a prorated earned bonus payment. In addition, if such termination occurs within 12 months following the occurrence of a change in control (as such term is defined in his employment agreement), Mr. Frank’s agreement also provides for 100% acceleration of his stock option and restricted share grants.

Angela Olsen

Ms. Olsen’s agreement provides that employment may be terminated by either us or Ms. Olsen. If Ms. Olsen’s employment is terminated by us without cause, as those terms are defined in her employment agreement, Ms. Olsen would be paid one year of continued base salary and benefits, starting on the date of termination and a prorated earned bonus payment.  In addition, if such termination occurs within 12 months following the occurrence of a change in control (as such term is defined in her employment agreement), Ms. Olsen’s agreement also provides for 100% acceleration of her stock option and restricted share grants.

401(k) Plan



We provide an employee retirement plan under Section 401(k) of the Internal Revenue Code (the “401(k) plan”), to all U.S. employees who are eligible employees as defined in the 401(k) plan. Subject to annual limits set by the Internal Revenue Service, we match 50% of eligible employee contributions up to a maximum of 3% of an employee’s salary, and vesting in our match is immediate. We made contributions in connection with the 401(k) plan during the years ended December 31, 2023 and 2022, of $113,255 and 2021, of $90,278 and $80,925,$94,278, respectively.



Registered Retirement Savings Plan



We also have a Registered Retirement Savings Plan for our Canadian employees. Subject to annual limits set by the Canadian government, we match 50% of eligible employee contributions up to a maximum of 3% of an employee’s salary, and vesting in our match is immediate. We made contributions in connection with this plan during the years ended December 31, 2023 and 2022, of $45,210 and 2021, of $44,038, and $38,336, respectively.



Indemnification of Officers and Directors



We have agreed to indemnify our directors and officers in certain circumstances. See “Related-Party Transactions, Policies, and Procedures- Agreements with Our Directors and Executive Officers.”

Compensation Risk Assessment



We believe that although a portion of the compensation provided to our executive officers and other employees is performance-based, our executive compensation program does not encourage excessive or unnecessary risk taking. This is primarily due to the fact that our compensation programs are designed to encourage our executive officers and other employees to remain focused on both short-term and long-term strategic goals, in particular in connection with our pay-for-performance compensation philosophy. As a result, we do not believe that our compensation programs are reasonably likely to have a material adverse effect on us.







RELATED-PARTYRELATED PERSON TRANSACTIONS, POLICIES, AND PROCEDURES



In addition to the director and executive compensation arrangements discussed above in the sections titled “Proposal 1 - Election of Directors” and “Executive Compensation, and Other Information,” we have been a party to the following transactions since January 1, 2021,2022, in which the amount involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets as of the end of the last two completed fiscal years, and in which any director, executive officer, or holder of more than 5% of any class of our voting stock, or any member of the immediate family of or entities affiliated with any of them, had or will have a direct or indirect material interest. We also describe below certain transactions and series of similar transactions since January 1, 2021,2022, with our directors, executive officers, holders of more than 5% of any class of our voting securities, or any member of the immediate family of or any entities affiliated with any of the foregoing persons to which we are party.



Agreements with Our Directors and Executive Officers



For more information regarding employment agreements with certain of our executive officers, see ‘‘Executive Compensation and Other Information-- Employment Agreements.’’



We have entered into agreements to indemnify our directors and executive officers. These agreements will, among other things, require us to indemnify these individuals for certain expenses (including attorneys’ fees), judgments, fines, and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our companyCompany or that person’s status as a member of our Board to the maximum extent allowed under Delaware law.



Relationship Agreement with TS Aquaculture

On October 29, 2019, Precigen and TS Aquaculture, a company that is managed by Third Security, entered into a stock purchase agreement, pursuant to which TS Aquaculture purchased from Precigen all shares of our Common Stock held by Precigen, and Precigen assigned to TS Aquaculture all of Precigen’s rights and obligations under a Relationship Agreement that Precigen entered into with us in December 2012 (the “Relationship Agreement”). The Relationship Agreement was entered into in connection with the acquisition in October 2012 by Precigen of 47.56% of our outstanding share capital from Linnaeus Capital Partners B.V. and Tethys, our former major stockholders.

The Relationship Agreement set forth certain matters relating to TS Aquaculture’s relationship with us as a major stockholder. Pursuant to the Relationship Agreement, so long as the Relationship Agreement remained in effect and TS Aquaculture and its affiliates together controlled 25% or more of the voting rights exercisable at meetings of our stockholders, we would (a) nominate such number of TS Aquaculture nominees as may be designated by TS Aquaculture for election to our Board at each annual meeting of our stockholders so that TS Aquaculture  would have representation on our Board proportional to TS Aquaculture’s percentage shareholding, rounded up to the nearest whole person, and (b) recommend that stockholders vote to elect such TS Aquaculture nominees at the next annual meeting of stockholders occurring after the date of nomination.

The Relationship Agreement and related documents also provided for certain confidentiality obligations between the two parties. The Relationship Agreement would continue in full force and effect until TS Aquaculture and its affiliates ceased to control 10% or more of the voting rights exercisable at meetings of our stockholders.  As of November 23, 2021, TS Aquaculture and its affiliates held approximately 7.5% of our outstanding Common Stock, and accordingly, the Relationship Agreement terminated pursuant to its terms.

Letter Agreement with TS Aquaculture



On July 30, 2021, the Companywe entered into a letter agreement (the “Letter Agreement”) with TS Aquaculture and certain of its affiliates that required us to file a registration statement to register the shares of Common Stock held by TS Aquaculture and certain of its affiliates and keep it effective for a period of not less than 24 months.  The registration statement was filed on August 5, 2021.  TS Aquaculture agreed to pay all expenses incurred in connection with such registration statements. We and TS Aquaculture also agreed to modify the terms of the Relationship Agreement between us and TS Aquaculture so as to restrict assignments of the rights of TS Aquaculture thereunder.



The entry into the Letter Agreement constituted a transaction with a “related party transaction”person” as defined by Item 404 of Regulation S-K because TS Aquaculture was an affiliate at that time and hashad appointed three members of our board pursuant to the Relationship Agreement.Board.  Pursuant to our policy, the Audit Committee is(“AC”) was responsible for the review and approval of any “related party transaction”, as such term is defined in Item 404 of Regulation S-K, afterthis transaction. After it hashad reviewed and considered all relevant facts and circumstances, including, but not limited to, whether the transaction iswas on terms comparable to those that could be obtained in an arm’s length transaction and the extent of the related party’sperson’s interest in the transaction.  As a result, entry into the Letter Agreement and this transaction was approved by the disinterested members of our Board on July 27, 2021, upon the recommendation of the Audit Committee.

AC.



As of December 31, 2022,On July 30, 2023, the registration statement filed pursuant to the Letter Agreement for the Common Stock held by TS Aquaculture and certain of its affiliates remained active.terminated pursuant to its terms.



Policies and Procedures for Review of Related Person Transactions



Our Board has adopted a written policy with respect to related person transactions. This policy governs the review, approval, and ratification of covered related person transactions. The Audit CommitteeAC of the Board manages this policy.



For purposes of this policy, a “related person transaction” is a transaction, arrangement, or relationship (or any series of similar transactions, arrangements, or relationships) in which we (or any of our subsidiaries) were, are, or will be a participant, and in which any related person had, has, or will have a direct or indirect interest. For purposes of determining whether a transaction is a related person transaction, the Audit CommitteeAC relies upon Item 404 of Regulation S-K promulgated under the Exchange Act.



A “related person” is defined as:





The policy generally provides that we may enter into a related person transaction only if: